Collectively, this paper shows that PPAR ligand is an important player as a member of the chemotherapeutic candidates for treating ER -negative breast cancer. (J Breast Cancer 2006;9: 293-300) 
INTRODUCTION
Breast cancer is the most common cancer and then leads to most of cancer deaths among women world-wide. A wide variety of chemotherapeutics are being explored to treat breast cancer. Anti-estrogen hormone therapy has been in best used for prevention and treatment in women with early breast cancer. (1) However, hormone therapy has little effect on estrogen receptor (ER )-negative tumors. (2) In deed, approximately 30% of breast cancer patients are negative for ER expression at diagnosis. Furthermore, approximately 50% of patients with advanced disease do not respond to first-line treatment with hormone therapy.(3) Therefore, resistance to hormone therapy causes a major problem in treatment and prevention of breast cancer. Thus, in order to overcome resistance to hormone therapy the novel treatment strategies should be explored.
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated nuclear receptors that mediate transcriptional regulation of genes involved in the oxidation, transport, and storage of lipids.(4-7) Among the three PPAR isoforms (PPAR , , and ), (8) (9) (10) ) PPAR influences such biological processes as inflammation, cell survival, differentiation, cell proliferation, and tumorigenesis.(11) Several ligands for PPAR have been identified including endogenous 15-deoxy- 12, 14 -prostaglandin J2, linoleic acid, lysophophatidic acid, and the thiazolidinediones class of synthetic antidiabetic drugs such as troglitazone and rosiglitazone. (12) (13) (14) (15) (16) (17) (18) In the other hand, PPARg ligand has recently been incriminated as a potential target for the prevention and treatment of human cancers. (17) In breast cancer, PPAR ligands also inhibit proliferation and induce apoptosis in ER -positive breast cancer cells. (19, 20) These reports indicate that PPAR ligand may prove to have a role in breast cancer treatment /prevention in the future. However, it has recently been known that ER negatively interferes PPAR signaling in breast cancer cells, (21) Therefore, we attempted to elucidate the role of PPAR in ER -negative breast cancer carcinogenesis and explore the possibility of using PPAR ligand as chemopreventive agent for hormone therapy-resistant breast cancer patients. In the current study, we determined if PPAR ligand induces cell-cycle arrest and apoptosis in ER -negative MDA-MB-231 breast cancer cell line. The observed apoptotic activity of PPAR ligand was accompanied by a cell cycle regulator induction such as p21. This paper shows the first time evidences that PPAR ligand plays as a primary member of chemotherapeutic candidates for ER -negative breast cancer. So, we expect the clinical use of PPAR ligand, which is more useful for in ER -negative breast cancers compared to ERpositive cancers.
METHODS

Materials
Anti-CDK (2, 4, 6) , cyclin (A, D1, D2, E), p21, p27, p-Rb, and PPAR were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Fetal bovine serum (FBS) and charcoal-dextran treated FBS were obtained from Gibco BRL (Life Technologies, Grand Island, USA). HBSS (Hanks balanced salt solution), MTT, propidium iodide, RPMI-1640, and ‚-actin antibody were obtained from Sigma Chemical Co. (St. Louis, USA). Ciglitazone, rosiglitazone, and troglitazone were purchased from ALEXIS Biochemicals (Lausen, Switzerland).
Cell culture
A human breast cancer cell line, MDA-MD-231 was obtained from the American Type Culture Collection (Rockville, USA). The cells were cultured in RPMI medium containing 10% fetal calf serum, 2 mM glutamine, antibiotics (Penicillin G 60 mg/L, Streptomycin 100 mg/L, Amphotericin B 50 /L) under a humid atmosphere (37 °C, 5% CO2).
MTT assay
The effect of PPAR ligands on cell viability of MDA-MB-231 cells was determined using MTT assay. Viability of cultured cells was determined by reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma, USA) to formazan. Briefly, cells of 1 10 4 cells/well were inoculated into a 96-well plate, treated with ciglitazone, rosiglitazone or troglitazone at various concentrations. After incubation for 72 h, cells were washed twice with phosphate-buffered saline (PBS), and MTT (100 /0.1 ml PBS) was added to each well. Cells were incubated at 37 °C for 1 h, and 100 ?l dimethyl sulfoxide (DMSO) was added to dissolve the formazan crystals. The plate was read in a microplate reader (model 3550, BIO-RAD, Richmond, USA) at 570 nm.
Cell cycle analysis
For analysis of cell cycle, 5 10 5 cells were seeded onto 6-well plates and treated with troglitazone at various concentrations for 48 h. At indicated times, cells were harvested by trypsinization, centrifuged at 1500 rpm for 3 min, washed with PBS, and fixed 1hour in 70% ethanol at 4 °C (fixed with 70% ethanol for 1h at 4 °C), and then collected by centrifugation, resuspended in PBS containing 5 /ml RNase and 50 /ml propidium iodide (PI), and incubated at 4 °C for 1h, protected from light. DNA content was analyzed using Becton Dickinson FACScan and Cell Quest software. Subsequent data analysis was performed using ModFit software (Becton Dickinson United Kingdom Ltd., Cowley, UK).
Western blot analysis
After washing with PBS and harvesting, cell pellets were lysed with the lysis buffer (50 mM Tris-HCl, pH 7.6, 1% Triton-X 100, 2 mM EDTA, 0.5% SDS, 150 mM NaCl, 1 mM sodium orthovanadate, 2 mM EGTA, 4 mM p-nitro-phenyl phosphate, and 100 mM sodium fluoride) supplemented with protease inhibitors (0.5% leupeptin, 0.5% aprotinin, and 0.02% phenylmethylslfonyl fluoride). After incubation for 30 min at 4 °C, cellular debris was removed by centrifugation at 10,000 g for 30 minute and supernatants were analyzed by 12% SDS-PAGE. Electrophoretic transfer from slab gel to nitrocellulose paper and subsequent immunoblotting was performed by incubation with primary antibodies and followed by further incubation with HRP-conjugated secondary antibody. Reactive proteins were detected using enhanced chemiluminescence (ECL, Amersham Life Sciences, Arlington Heights, USA).
TUNEL staining
Detection of apoptosis in breast cancer cell was carried out using a DNA fragmentation assay based on terminal deoxynucleotidyl transferase (TdT)-mediated dUTP digoxigenin nick-end-labeling (TUNEL). Briefly, MDA-MB-231 breast cancer cells plated on glass coverslips in 24-well culture plates were grown at 37 °C for 24 h, troglitazone was added and incubated for an additional 48 h. The cells were then fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS) for 15 min, washed with PBS, and incubated in 0.3% H2O2 to block endogenous peroxidases and incubated with a TUNEL reaction mixture (terminal deoxynucleotidyl transferase, nucleotide mixture, Roche, Mannheim, Germany) at 37 °C for 1 h, and then the sections were washed with distilled water (D/W). They were then reincubated in anti-fluorescein antibody conjugated with horse-radish peroxidase at room temperature for 30 min, re-washed, and then visualized using the ABC technique and 0.05% 3,3'-diamino-benzidine (DAB, Sigma, USA) as a chromogen. The slides were counterstained with hemotoxylin and mounted on cover slip. Condensed and fragmented nuclei with the brown label were considered apoptotic when visualized by light microscopy. The numbers of TUNEL positive cells were counted by a pathologist: at 200 magnification, 30 fields/section. The TUNEL-positive cells were counted separately in the gray and white matter at ten axial levels. 
Hoechst staining
For morphological examination of apoptotic changes, cells were stained with Hoechst 33342 (Calbiochem, San Diego, USA). Human breast cancer cells plated on glass coverslips in 6-well culture plates were grown at 37 °C for 24h. Troglitazone was added and incubated for an additional 48 h. The cells were fixed for 15 min at room temperature in 4% paraformaldehyde and then washed with PBS. Fixed cells were incubated for 30 min at room temperature with Hoechst 33342 (
Statistical Analysis
All experimental data are mean standard error (SE). Statistical analysis was performed using Student's t-test, and p < 0.005 was considered to be significant. (Fig 1) . This result was similar to other hepatoma cancer cells responding to troglitazone. (24) These results indicate that PPARg-regulated genes play a pivotal role in the carcinogenesis of ER -negative MDA-MB-231 breast cancer cells. (Fig 3) . In troglitazone-treated MDA-MB-231 cells, the percentage of G1 phase was maintained in elevated levels, indicating that troglitzone induces G1 arrest in ER -negative MDA-MB-231 cells. Troglitazone induces G1 cell cycle arrest in ERpositive MCF-7 cells. (19) These results suggest that troglitazone-mediated G1 arrest in breast caner cells is independent of estrogen receptor.
RESULTS AND DISCUSSION
Troglitazone induces expression of PPAR in
MDA-MB-231 cells
Troglitazone-mediated growth inhibition is associated with decreased levels of G1 Cdks and D-type cyclins and increased p21 and p27 protein levels in
MDA-MB-231 cells
The cell cycle is tightly regulated through a complex network of positive and negative regulatory molecules including cyclin dependent kinase (Cdks), cyclin, and Cdk inhibitor (Cdki). To elucidate the role of these molecules in the inhibition of cell cycle induced by troglitazone in MDA-MB-231 breast cancer cells, protein extract was prepared from the cells treated with various concentrations of troglitazone for 48 h. Western blot was performed using antibodies against pRb, cyclin D1, cyclin D2, cyclin D3, p21, p27, cdk2, Cdk4 and Cdk6. As shown in Fig 4, troglitazone treatment dose-dependently caused a marked decrease in pRb, cyclin D1, cyclin D2, cyclin D3, cdk2, Cdk4 and Cdk6 expression * and a significant increase in p21 and p27 expression.
Troglitazone induces apoptosis in MDA-MB-231 cells
Apoptosis is a distinctive form of cell death that can result in the deletion of specific cell populations during physiologic processes. The growth inhibition by troglitazone treatment in MDA-MB-231 cells appeared to occur dependently of apoptosis. The ability of troglitazone to induce apoptosis in MDA-MB-231 breast cancer cells was initially determined by the DNA fragmentation assay based on TUNEL staining and Hoechst staining. When MDA-MB-231 breast cancer cells were exposed to various concentrations of troglitazone for 48 h, they exhibited DNA fragmentation positive cells on TUNEL staining (Fig 5) .
Apoptotic cells by TUNEL staining elevated from 2.5-fold of the control level at 10 M, to 3.1-fold at 50 M and to 3.5-fold at 75 M. Furthermore, MDA-MB-231 cells exposed to troglitazone exhibited typical morphological changes of apoptosis including cytoplasmic and nuclear shrinkage, chromatin condensation and fragmentation after staining with Hoechst 33342 (Fig 6) .
CONCLUSION
This study addresses for the first time ER -negative breast cancer cell growth and apoptosis may be modulated through PPAR . MDA-MB-231 cells exposed to troglitazone showed a G1 cell cycle arrest as well as induction of morphological changes characteristic of apoptosis. Moreover, troglitazone caused significantly increase in p21 and p27 expression.
Our results suggest that troglitazone has potent effect on ER -negative breast cancer growth and may prove to have a role in hormone therapy-resistant breast cancer treatment /prevention in the future. However, the therapeutic implications of the troglitazone growth-inhibitory effect on ER -negative human breast cancer cells still need to be studied. Further research is necessary to establish possible therapeutic approaches using troglitazone or modified analogs of the thiazolidinedione class of drugs. 
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Eun Jeong Jo, et al. Detection of apoptosis in breast cancer cell was carried out using a DNA fragmentation assay based on TUNEL staining. MDA-MB-231 breast cancer cells were cultured on 6 well plates and treated with troglitazone for 48h at various concentrations. Positive nuclei stained brown, and negative nuclei stained blue. Error bars, SE; n=3 in each group (* p<0.005 versus zero concentration). 
